Three studies have been indicated as noteworthy:
Abstract 164O
First perspective pre-planned and adequately sized study for evaluation of KRAS in non-small cell lung cancer patients who seem to have a higher risk of progression
Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B
Abstract 166O
Favorable clinical benefit of potential new therapy with dacomitinib and improvements in common disease-related symptoms
Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B
Abstract 77O
Validation of favorable prognostic role for survival of tumor lymphocytic infiltration in resectable non-small cell lung cancer
Proffered Paper session, Friday, April 20, 14:30-16:00, Room C
Provided by European Society for Medical Oncology
This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.
